Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal

BACKGROUND: The introduction of eculizumab has significantly improved the outcome of patients with atypical haemolytic uraemic syndrome (aHUS). Because of the risk of relapse after discontinuation, eculizumab was proposed as life-long therapy. However, data on the outcome of relapse are limited. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Duineveld, Caroline, Bouwmeester, Romy, van der Heijden, Joost W, Berger, Stefan P, van de Kar, Nicole C A J, Wetzels, Jack F M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496203/
https://www.ncbi.nlm.nih.gov/pubmed/34631043
http://dx.doi.org/10.1093/ckj/sfaa241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496203/
https://www.ncbi.nlm.nih.gov/pubmed/34631043
http://dx.doi.org/10.1093/ckj/sfaa241

Ejemplares similares